Background
A vast amount of epidemiological evidence now points towards lipoprotein(a) (Lp[a]) as a strong, genetically determined independent risk factor for cardiovascular disease (CVD).1 Despite this growing body of evidence, challenges and barriers remain globally in the identification of patients with raised Lp(a) levels. The European Atherosclerosis Society (EAS) Lipid Clinics Network conducted a survey involving a total of 151 centres to identify and understand how and when Lp(a) is tested and clinically evaluated in lipid clinics throughout Europe, and the challenges that may prevent evaluation.2 The survey found that 75.5% of clinic
